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Abstract
The G protein-coupled receptors (GPCRs), which form the largest group of transmembrane proteins involved in signal
transduction, are major targets of currently available drugs. Thus, the search for cognate and surrogate peptide ligands for
GPCRs is of both basic and therapeutic interest. Here we describe the application of an in vitro DNA display technology to
screening libraries of peptide ligands for full-length GPCRs expressed on whole cells. We used human angiotensin II (Ang II)
type-1 receptor (hAT1R) as a model GPCR. Under improved selection conditions using hAT1R-expressing Chinese hamster
ovary (CHO)-K1 cells as bait, we confirmed that Ang II gene could be enriched more than 10,000-fold after four rounds of
selection. Further, we successfully selected diverse Ang II-like peptides from randomized peptide libraries. The results
provide more precise information on the sequence-function relationships of hAT1R ligands than can be obtained by
conventional alanine-scanning mutagenesis. Completely in vitro DNA display can overcome the limitations of current
display technologies and is expected to prove widely useful for screening diverse libraries of mutant peptide and protein
ligands for receptors that can be expressed functionally on the surface of CHO-K1 cells.
Citation: Doi N, Yamakawa N, Matsumoto H, Yamamoto Y, Nagano T, et al. (2012) DNA Display Selection of Peptide Ligands for a Full-Length Human G Protein-
Coupled Receptor on CHO-K1 Cells. PLoS ONE 7(1): e30084. doi:10.1371/journal.pone.0030084
Editor: Maria Gasset, Consejo Superior de Investigaciones Cientificas, Spain
Received August 9, 2011; Accepted December 9, 2011; Published January 10, 2012
Copyright:  2012 Doi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Research for Promoting Technological Seeds grant (09-479) from the Japan Science and Technology Agency; the
Industrial Technology Research Grant Program (03A01007a) and a Grant for Practical Application of University Research & Development Results under the
Matching Fund Method from the New Energy and Industrial Technology Development Organization of Japan; a Grant-in-Aid for Scientific Research (19360377)
from the Japan Society for the Promotion of Science; and a Special Coordination Fund grant from the Ministry of Education, Culture, Sports, Science and
Technology of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: doi@bio.keio.ac.jp
¤ Current address: Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Introduction
The superfamily of G protein-coupled receptors (GPCRs) [1] is
the largest and most diverse group of cell-surface proteins involved
in signal transmission. Although a large number of GPCRs has
been identified in the human genome project [2,3], more than 100
of them have no known physiologically relevant ligand yet [4,5],
and they are classified as orphan GPCRs. Since GPCRs are major
targets for today’s drugs [6], the search for cognate and surrogate
peptide ligands for GPCRs is of both basic and therapeutic interest
[7,8]. Conventional analysis of the specificity of the interaction
between GPCRs and peptide ligands involves the mutation of
individual amino acids by peptide synthetic methods (e.g., Ala-
scanning), followed by measurement of binding affinity or receptor
activation. However, the sequence space that can be searched with
this standard strategy is quite limited.
As a powerful alternative strategy, phage display has been used to
screen peptides that bind to GPCRs expressed on mammalian cells
[9–13], but the library sizes and the sequence varieties in a phage
library are limited by the transformation efficiency and biological
constraints of the host bacteria. This limitation can potentially be
overcome by using totally in vitro selection systems, such as ribosome
display and mRNA display, whichemploy cell-free protein synthesis
[14–17]. Recently, mRNA display was used to screen peptide
ligands that bind to the N-terminal extracellular domain of a class B
GPCR immobilized on beads [18], but such an RNA-tagging
method requires strictly RNase-free conditions and cannot easily be
applied to selection targeting full-length GPCRs expressed on the
cell surface.
We have previously developed a DNA display system called
STABLE (STreptAvidin-Biotin Linkage in Emulsions) [19–21], in
which streptavidin-fused peptides are linked with their encoding
DNA via biotin labels in a cell-free transcription/translation system
compartmentalized in water-in-oil emulsions. This method allows
completely in vitro selection of a stable DNA-tagged peptide library
with large diversity in the presence of RNase. In this study, we
applied the DNA display system to in vitro selection of peptide
ligands for a full-length GPCR expressed on whole cells. As a
model to test our screening strategy, we used a well-known GPCR,
human angiotensin II (Ang II) type-1 receptor (hAT1R), which is
significantly involved in cardiovascular diseases. Under improved
selection conditions using hAT1R-expressing mammalian cells as
bait, the Ang II gene was enriched from model libraries (1:100 or
1:10,000 mixture of streptavidin-fused Ang II and streptavidin
genes). Further, various Ang II-like peptides were successfully
selected from randomized peptide libraries, and their binding
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30084activity and biological function were characterized to elucidate the
sequence-function relationship of hAT1R ligands.
Results
Strategy for in vitro selection of GPCR-ligands
We improved and applied the STABLE DNA display system
[19–22] for in vitro selection of GPCR-ligands on whole cells
(Fig. 1). In this system, the linkage of DNA (genotype) and peptide
(phenotype) was accomplished in water-in-oil emulsions containing
an in vitro transcription/translation system, in which one DNA
molecule was caged in each reversed micelle on average [23]. A
stable binding of streptavidin with biotin was used as the connector
between DNA and its translated products [19]. The number of
DNA-peptide conjugates in a library (i.e., library size) is
comparable with the number of emulsion droplets (10
9–10
10 per
1 ml of emulsion). The DNA-displayed peptide library was
incubated with GPCR-expressing cells in the presence of a
GRGDS pentapeptide to inhibit undesired binding of an RGD-
like sequence within streptavidin to integrins on the cell surfaces
[24]. We also added 0.5 M sucrose to the binding buffer to inhibit
internalization of agonist peptides by receptor-mediated endocy-
tosis [25]. Furthermore, in order to repress the large background
of cell-surface proteins, glycans and lipids, the library was pre-
incubated with ‘Mock’ cells without recombinant GPCR to
remove nonspecific binders before incubation with the GPCR-
expressing cells (not shown in Fig. 1). A Chinese hamster ovary cell
line CHO-K1 is suited for this purpose, because CHO-K1 is a
preferred non-human cell line for the efficient and stable
expression of a variety of recombinant human proteins including
GPCR [26]. Finally, we used a photocleavable 2-nitrobenzyl linker
[27] between DNA and peptide for rapid and efficient recovery of
selected DNA from DNA-peptide conjugates bound to GPCRs by
means of simple photocleavage [22].
Enrichment of angiotensin II genes on the hAT1R-
expressing cells
As a model GPCR and its ligand, the human angiotensin II type
1 receptor (hAT1R) and octapeptide angiotensin II (Ang II; Asp
1-
Arg
2-Val
3-Tyr
4-Ile
5-His
6-Pro
7-Phe
8) were used here. Stable ex-
pression of recombinant hAT1R with a C-terminal c-myc tag on
CHO-K1 cells was confirmed by immunostaining with anti-c-myc
antibody (Fig. 2A). The binding of Ang II to the hAT1R/CHO-
K1 cells was confirmed by radio ligand binding assay: the
dissociation constant and the number of ligand binding sites were
estimated as Kd=8.2 nM and 8.3610
5 binding sites/cell,
respectively (data not shown). In addition, the function of the
recombinant hAT1R was confirmed by monitoring the change in
intracellular calcium in response to Ang II (Fig. 2B). These results
indicate that a sufficient amount of the model GPCR, hAT1R,
was expressed on cell membranes in active form(s), and thus,
hAT1R can serve as a bait receptor protein for further in vitro
selection experiments.
To confirm whether not only Ang II peptides, but also
streptavidin-fused Ang II proteins can bind to hAT1R, streptavi-
din-Ang II genes with the generally-used linkers were in vitro
transcribed and translated, and the products were incubated with
the hAT1R/CHO-K1 cells. It was found that the peptide fused
with streptavidin through a helical linker [28] (four repeats of
‘GAAAK’) efficiently and specifically bound to the hAT1R/CHO-
K1 cells, while the fusion protein with a Gly-rich flexible linker
(five repeats of ‘SGGGG’) nonspecifically bound to both the
hAT1R/CHO-K1 and the Mock CHO-K1 cells, and the fusion
Figure 1. Schematic representation of DNA display selection of peptide ligands for GPCR expressed on cells. A streptavidin gene-fused
random DNA library labeled with biotin through a photocleavable linker is introduced into an in vitro transcription/translation system (Step 1). A
single DNA molecule compartmentalized in a reversed micelle of water-in-oil emulsions is transcribed and translated in vitro (Step 2). In each
compartment, a translated streptavidin-fused peptide (phenotype) binds to its encoding DNA (genotype) via the biotin label, and a mixture of DNA-
peptide conjugates is recovered from the emulsions (Step 3). The resulting DNA-displayed random peptide library is affinity-selected with GPCR-
expressing mammalian cells, and the DNA portion of binding molecules is eluted by photocleavage (Step 4). The selected DNA is amplified by PCR
(Step 5) and used for the next round of enrichment (Step 6) or cloning and sequencing (Step 7).
doi:10.1371/journal.pone.0030084.g001
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shown), perhaps due to steric hindrance. The results indicate that
a peptide ligand can specifically bind to its receptor expressed on
CHO-K1 cells even if the large streptavidin tetramer is fused with
the peptide through the helical linker.
By using the hAT1R-expressing cells as bait, we demonstrated
that genes encoding streptavidin-fused angiotensin II (termed
STA-Ang II) could be selected from at least a 10
4-fold excess of
genes encoding streptavidin without Ang II (termed STA) using
the improved DNA display. The STA-Ang II and STA genes were
mixed in a ratio of 1:100 or 1:10,000, and then subjected to several
rounds of the DNA display selection procedure using water-in-oil
emulsions (Fig. 1). Two rounds of selection of the 1:100 ratio of
STA-Ang II: STA genes and four rounds of selection of the
1:10,000 ratio each resulted in a roughly 1:1 final gene ratio,
indicating an enrichment factor of about 10-fold per round (Fig. 3).
This enrichment efficiency is comparable with that in our previous
studies using bait-immobilized beads [19,20].
In vitro selection of randomized peptide libraries
Next, we applied the DNA display method to selection of
randomized peptide libraries on whole cells. Since early studies
using synthetic analogues of Ang II revealed that Arg
2, Tyr
4 and
Phe
8 in Ang II directly interact with hAT1R [29–31], the three
residues were fixed in the randomized Ang II library-I. The DNA-
displayed randomized peptide library-I was captured on the
hAT1R/CHO-K1 cells, which were then washed, and exposed to
UV irradiation for elution. After five rounds of selection, DNA was
PCR-amplified and cloned. Randomly chosen clones were
analyzed by DNA sequencing, and the binding activity of each
distinct, in-frame clone was further confirmed (see next section for
details). Consequently, five Ang II-like sequences were obtained
(Fig. 4A, Binding, +). Not only fixed residues Arg
2, Tyr
4 and Phe
8,
but also the residues His
6 and Pro
7 of the original Ang II sequence
were conserved at frequencies of 100% (Fig. 4B). Other residues
Asp
1 and Val
3 did not appear (0%) in the selected clones, while
Ile
5 was also highly conserved (Fig. 4B).
To investigate whether the residues Arg
2, Tyr
4 and Phe
8 in Ang
II fixed in the library-I are truly essential for binding to hAT1R,
we further constructed and screened the randomized Ang II
library-II, in which the 2nd, 4th and 8th positions were
randomized, while His
6 and Pro
7 were fixed. The sequencing
and binding analyses revealed that the residues Arg
2 and Tyr
4
were conserved at frequencies of 80 and 100%, respectively, while
Phe
8 did not appear (0%) in the selected clones (Fig. 5B).
Characterization of the selected peptides
As mentioned above, we first investigated the binding activities
of streptavidin-fused peptides selected from the library-I (Fig. 4A)
and the library-II (Fig. 5A). Each streptavidin-fused peptide was
produced independently and captured on the hAT1R-expressing
CHO-K1 cells. Then the cells were washed, and residual proteins
were detected by Western blotting. As shown in Figure 6, 12 out of
18 peptides specifically bound to hAT1R/CHO-K1 cells. LI5-7
and LII3-8 nonspecifically bound to the Mock/CHO-K1 cells
with the empty vector alone, as well as the hAT1R/CHO-K1
cells. LI5-5, LI5-9, LII3-9 and LII3-10 (not shown) did not bind to
hAT1R/CHO-K1. Although nonspecific binding to the Mock/
CHO-K1 cells was also seen for LI5-1 to LI5-4, especially for LI5-
2, each band for the Mock/CHO-K1 cells is weaker than that for
Figure 2. Stable expression of a model GPCR, the recombinant
human angiotensin II type 1 receptor (hAT1R) with the C-
terminal c-myc tag, on CHO-K1 cells. (A) Immunofluorescence
staining of hAT1R-c-myc-expressing CHO-K1 cells (hAT1R/CHO-K1, left)
and CHO-K1 cells transfected with the empty vector alone (Mock/CHO-
K1, right) with anti-c-myc antibody (green). Nuclei were stained with PI
(red). (B) Confirmation of the function of hAT1R-c-myc by monitoring
changes in intracellular Ca
2+ in response to angiotensin II (Ang II). Fura-
2/AM-loaded hAT1R/CHO-K1 or Mock/CHO-K1 cells were exposed to
1 nM Ang II at the point indicated by the arrow. The results are
expressed as Fura-2 fluorescence ratio (340/380 nm).
doi:10.1371/journal.pone.0030084.g002
Figure 3. Construction and enrichment of the streptavidin-
fused angiotensin II (STA-Ang II) gene in multiple rounds of
DNA-display selection on hAT1R/CHO-K1 cells. (A) A schematic
representation of the DNA template for in vitro transcription/translation.
DNA was labeled during PCR with photocleavable biotin [22] at the
upstream ends and with fluorescein at the downstream ends, using
labeled primers. The translated open reading frame consists of
sequences for a T7?tag, streptavidin (STA), a peptide linker, and Ang II
gene. The 59-UTR fragment contains T7 promoter. (B) Reaction mixtures
containing 1:100 or 1:10,000 molar ratio of STA-Ang II: STA genes were
emulsified. The DNA after each round of selection was PCR-amplified
with a fluorescein-labeled primer and analyzed by 15% PAGE with an
imaging analyzer.
doi:10.1371/journal.pone.0030084.g003
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candidates for further characterization.
To clarify whether the selected 12 peptides bind to hAT1R in
the same manner as Ang II, we next performed competitive
binding assays. Except for LI5-3, the peptides bound to hAT1R/
CHO-K1 cells only in the absence of the Ang II competitor (Fig. 7),
indicating that the selected peptides do interact with hAT1R at the
Ang II-binding site. Again, some content of LI5-2 non-specifically
bound to the cell-surface (Fig. 6) and thereby seems not to be
completely competed out by Ang II (Fig. 7). A reason may be a
relatively higher hydrophobicity of LI5-2 peptide with Trp
1 in
comparison with other peptides having hydrophilic amino acids
such as Asn, His or Arg at the position 1.
Furthermore, IC50 values were determined by means of
competitive binding assays at various concentrations of synthe-
tic peptides (Fig. S1) for the frequent clones LI5-1 (71 clones) and
LI5-2 (13 clones), as shown in Figure 4A, as well as LII3-2 (26
clones), LII3-4 (13 clones) and LII3-5 (12 clones), shown in
Figure 5A.
Finally, we confirmed the biological activity of selected peptides
by calcium imaging (Fig. 8). The concentration of calcium in the
hAT1R-expressing cells increased in response to LI5-1, LI5-2,
LII3-2 and LII3-4, indicating that these peptides have agonist
activity, like Ang II (Fig. 8A-D). On the other hand, LII3-5 did not
enhance the calcium concentration, but inhibited the effect of Ang
II (Fig. 8E), indicating that this peptide has antagonist activity.
Discussion
In this study, completely in vitro selection of peptide ligands for a
full-length GPCR expressed on whole cells was accomplished by
using an in vitro DNA display technology. With Ang II receptor as
a model GPCR, wild-type and mutated Ang II peptides were
successfully selected from model libraries and randomized peptide
libraries, respectively. As shown in Fig. 3, when only Ang II was
the binding sequence in the doped library, the Ang II sequence
was selected from the model library. However, no wild-type
sequence was selected from the randomized libraries, though a
variety of Ang II-like peptides were identified (Figures 4 and 5).
The constrained random libraries contain a variety of binding
sequences, some of which become fixed by random genetic drift
Figure 4. Amino acid sequences of selected clones from the
randomized library-I. (A) The designed sequence is XRVYVXVF
where X=F, L, I, M, V, S, P, T, A, Y, H, Q, N, K, D, E, C, W, R or G; and V=F,
L, I, M, V, S, P, T or A. Fixed residues are shown in blue, and conserved
residues are red. The number of clones containing each sequence is
indicated. Sequences of seven clones with a frameshift in the preceding
linker region are not shown. The binding activity (+, specific binding; +/
2, nonspecific binding; 2, no binding) of each peptide is also shown in
Figures 6 and 7. IC50 was determined by means of competitive binding
assays at various concentrations of synthetic peptides (see MATERIALS
AND METHODS and Figure S1). (B) Sequence logos representation
[45,46] of the peptide sequences with specific binding activity (+). The
height of each column reflects the bias from random of particular
residues. Fixed residues are shown in gray. Polar amino acids containing
an amide group (Q, N) and the rest of them are shown in purple and
green, respectively, basic charged residues in deep blue, and
hydrophobic residues in black.
doi:10.1371/journal.pone.0030084.g004
Figure 5. Amino acid sequences of selected clones from the
randomized library-II. (A) The designed sequence is XXYXHHPV
where X=F, L, I, M, V, S, P, T, A, Y, H, Q, N, K, D, E, C, W, R or G; Y=F,L,I
or V; H=I or L; and V=F, L, I, M, V, S, P, T or A. Sequences of four clones
(including LII3-3) with a frameshift in the preceding linker region are not
shown. Fixed residues are shown in blue, and conserved residues are
red. (B) Sequence logos representation. For details, see the legend of
Figure 4.
doi:10.1371/journal.pone.0030084.g005
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selection experiments (e.g., Refs. [9–13]) to be failed to pick up
native peptide sequences from partially or completely randomized
peptide libraries.
The analysis of the selected peptides revealed that the residues
Arg
2, Tyr
4, His
6 and Pro
7 in Ang II are important for binding to
hAT1R. This result is consistent with the previous finding that the
binding affinity of synthetic Ang II to hAT1R was affected by Ala
substitution at positions 2, 4, 6 and 7, respectively (Kd.10 mM)
[32]. However, LII3-5 with Lys
2 retains affinity as high as that of
wild-type Ang II (Fig. 5A), which is inconsistent with the previous
study [33]: the affinity of [Lys
2]Ang II for rat AT1R was lower
than that of wild-type Ang II.
While the residue Phe
8 is important for high agonist activity
[29,31], a series of Ang II analogs mutated at the C-terminal
position 8 (e.g., Ile
8 and Leu
8) exhibit antagonist activity [34,35].
However, the selected peptides LII3-2 with Ile
8 and LII3-4 with
Leu
8 possess agonist activity (Fig. 8C,D), indicating that
nonconserved positions 1 and 3 are also important in determining
the function of Ang II-like peptides. Furthermore, the shapes of the
calcium fluxes for the mutated peptides are somewhat different
from that for wild-type Ang II. It may reflect a possible different
signaling by the selected peptides, because there is a growing body
of literature suggesting that different ligands bind to and activate
the same GPCR through different signaling pathways [36,37].
Thus, further studies for selection of peptide ligands have the
potential to contribute to the GPCR biology in the future.
The use of DNA display for searching peptide ligands offers
several advantages over other display technologies, such as phage
display and mRNA display. First, as mentioned in the introduc-
tion, the size of DNA display libraries based on cell-free protein
synthesis is usually greater than that of phage libraries using
bacterial expression, and the chemical stability of DNA permits
selection targeting full-length GPCRs expressed on cell-surface,
where RNA would be easily degraded. Further, each peptide in
the conventional phage display and mRNA display libraries should
be linked with its genotype at the C-terminus, while a peptide can
be fused with both N- and C-terminals of streptavidin in DNA
display [38]. The free N- or C-terminus of peptide ligands is often
important for their biological activities. Finally, the use of the
reconstituted transcription/translation system in DNA display
allows various applications; for example, the incorporation of
unnatural amino acids [39,40] for in vitro selection of peptide
mimetic compounds. Thus, the method we describe should prove
useful not only for the mutation analysis of ligand/receptor
interaction, but also for screening of agonists and antagonists for
disease-related GPCRs that can be expressed functionally on the
surface of CHO-K1 cells, and for the identification of peptide and
protein ligands for orphan GPCRs except for those with non-
peptide endogenous ligands.
Materials and Methods
Preparation of GPCR-expressing mammalian cells
The hAT1R gene (1080 bp) [41] was amplified from a human
liver cDNA library (from Prof. J.-I. Inoue; Institute of Medical
Science, University of Tokyo) by means of PCR with Ex Taq
DNA polymerase (Takara Shuzo) using the primers hAT1R-F
and hAT1R-R (all primer sequences used in this study are listed
in Table S1). The PCR product was digested with EcoRI and
XbaI and then cloned into the identical restriction-enzyme sites
of a vector pEF1/myc-HisA (Invitrogen) comprising an EF1a
promoter and fusion-tag sequences encoding C-terminal c-myc
and polyhistidine tags. The resulting plasmid pEF1-hAT1R-
MycHis was confirmed with an ABI PRISM 3100 genetic
analyzer (Applied Biosystems), purified with an endofree plasmid
maxi kit (Qiagen), and used for transformation of the
mammalian cell line CHO-K1 [a Chinese hamster ovary cell
line purchased from RIKEN Cell Bank (Ibaraki, Japan) in 2000]
with lipofectamine 2000 (Invitrogen). As a control, CHO-K1
cells were also transfected with the empty vector alone (Mock/
CHO-K1). The transfected cell lines were kept under selection
pressure of 400 mg/ml G418. The expression of the recombinant
hAT1R was confirmed by Western blot analysis of cell lysates
using mouse anti-c-myc monoclonal antibody (MBL) and an
ECL plus Western blotting analysis system (Amersham Biosci-
ences).
Figure 6. Binding assays of selected peptides from the random-
ized libraries with the hAT1R-expressing cells. Selected streptavi-
din-fused peptides were generated by the PURE system. An aliquot of
the reaction mixture was incubated with the hAT1R/CHO-K1 cells
(hAT1R +) or the Mock/CHO-K1 cells (hAT1R 2). The cells were washed,
and the bound molecules were detected with anti-T7?tag antibody. The
sequences of the peptides are shown in Figures 4A and 5A.
doi:10.1371/journal.pone.0030084.g006
Figure 7. Competitive binding assays. Selected streptavidin-fused
peptides were incubated with the hAT1R/CHO-K1 cells in the presence
(+)ortheabsence(2)ofthefreeAngIIpeptide(100 nM)asacompetitor.
For details, see the legend of Figure 6 and MATERIALS AND METHODS.
doi:10.1371/journal.pone.0030084.g007
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The hAT1R-expressing mammalian cells were plated on a micro
cover glass sunk in complete medium [10% (v/v) FBS, 90% (v/v)
Ham’s F-12, 100 units/ml penicillin, 100 mg/ml streptomycin,
400 mg/ml G418] and incubatedfor 48 h at 37uC inan atmosphere
of 5% CO2 in air. Prior to immunostaining, cells were fixed in
PBST with 3.7% paraformaldehyde for 10 min at room temper-
ature,treated with0.1 mg/mlRNaseA (DNase-free;Invitrogen)for
20 min at 37uC, and blocked in PBS with 1% BSA for 30 min at
room temperature. Antibodies were diluted in PBS with 1% BSA.
Immunofluorescence staining was performed with mouse anti-c-
myc monoclonal antibody (Santa Cruz Biotechnology) for 45 min
at room temperature. The cover glass was washed three times with
PBS, incubated with goat anti-mouse Alexa Fluor 488-conjugated
antibody (Molecular Probes) for 50 min and washed three times
with PBS. For nuclear staining, the cover glass was incubated with
500 nMpropidiumiodide(PI;MolecularProbes)in26SSC(0.3 M
NaCl, 30 mM sodium citrate, pH 7.0) for 5 min at room
temperature and washed three times with 26SSC. Then the cover
glass was inverted and set on a slide glass. The slides were viewed
with a confocal microscope (Nikon Eclipse E600 microscope and
Bio-RadRadiance2000 scanningsystem) forAlexa Fluor488 (495/
519 nm) and PI (536/617 nm).
Radio ligand binding assays
Cells were harvested in 48-well plates (IWAKI) at a density of
approximately 6610
5 cells/well. The cells were blocked with
Ham’s F12 medium containing 1% BSA, then [
125I]Sar
1,Ile
8-Ang
II was added (2,000 Ci/mmol; Amersham Biosciences; final
concentration in 150 ml final volume ranging from 0.05 nM to
20 nM). After incubation for 30 min at room temperature, the
cells were washed three times with 500 ml of PBS containing 1%
BSA and radioactivity was counted with a MINAXI auto-gamma
5000 scintillation counter (Canberra-Packard). Values for receptor
capacity and affinity were obtained by Scatchard analysis.
Calcium imaging
The intracellular concentration of calcium [Ca
2+]i was mea-
sured by incubating hAT1R-expressing cells with the fluorescent
Ca
2+ indicator, 1-[6-amino-2-(5-carboxy-2-oxazolyl)-5-benzofura-
nyloxy]-2-(2-amino-5-methylphenoxy)ethane-N,N,N9,N9-tetraace-
tic acid penta-acetoxymethyl ester (Fura-2/AM) as previously
described [42]. Briefly, the cells in fresh BSS (balanced salt
solution; 20 mM HEPES, pH 7.3, 130 mM NaCl, 5.4 mM KCl,
5.5 mM D-glucose, 1.8 mM CaCl2 and 0.8 mM MgSO4) were
loaded at 37uC for 30 min with 5 mM Fura-2/AM, conditioned in
flowing BSS at 37uC, then exposed to the stimulating reagent Ang
II or synthetic peptides for selected clones by changing the BSS
flow to peptide-containing BSS flow for 30 s. The fluorescence of
the cells was then measured at the emission wavelength of 510 nm
with sequential excitation at 340 nm and 380 nm. The 340/380
ratio can be converted to [Ca
2+]i according to the formula
presented by Grynkiewicz et al. [43].
Preparation of DNA libraries
Two libraries of streptavidin-fused random peptides were
amplified by three steps of PCR from a pSta4-derived plasmid
[20] carrying a streptavidin gene with the N-terminal T7?tag and
the C-terminal helical peptide linker by the 1st step PCR with Ex
Taq DNA polymerase, using forward primer T7tagF-M and
reverse primer HL4-SG-RYF-NYN-R (for library-I) or HL4-SG-
MTH-NTN-NYN-R (for library-II) (Table S1). Each PCR
product was re-amplified using forward primer T7F-M and
reverse primer T7R-M (library-I) or T7R-M2 (library-II), and
finally re-amplified using photocleavable biotin (PCB)-labeled T7F
and T7R primers. The PCR products were purified with a
Figure 8. Effect of selected peptides on the concentration of calcium in the hAT1R-expressing cells. Fura-2/AM-loaded hAT1R/CHO-K1
or Mock/CHO-K1 cells were exposed to synthetic octapeptides (A) LI5-1 (10 nM), (B) LI5-2 (10 nM), (C) LII3-2 (10 nM), (D) LII3-4 (100 nM), and (E) LII3-
5( 1mM) and/or Ang II (1 nM), respectively, as indicated by the arrows. The results are expressed as Fura-2 fluorescence ratio (340/380 nm).
doi:10.1371/journal.pone.0030084.g008
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DNA fragment encoding a streptavidin-Ang II fusion protein (a
positive control) and a streptavidin gene without Ang II (a negative
control) were amplified by three-step PCR using reverse primer
HL4-AT2-R or HL4-R, respectively, in the 1st step. All PCR
programs consisted of 15–25 cycles of denaturation at 98uC for
10 s, annealing at 60uC for 30 s, and extension at 72uC for 1 min.
Preparation of DNA-displayed peptide libraries
In vitro transcription/translation reactions in water-in-oil emul-
sions were performed as previously described [19,23] with the
following modifications. The PURE system classic II kit (Post
Genome Institute Co., Ltd.) based on a reconstituted E. coli
transcription/translation system [44] was used as the water phase,
and mineral oil (Nacalai Tesque) containing 4.5% (v/v) Span85
(Nacalai Tesque) and 0.5% (v/v) Tween80 (Nacalai Tesque) was
used as the oil phase. The DNA concentration was 50 pM in each
round of selection except for the first round, in which it was
200 pM, and the fifth round, in which it was 10 pM. The amounts
of emulsion were 10 ml (including 500 ml of PURE system) for the
first round, 4 ml (200 ml) for the second round, 2 ml (100 ml) for the
third round, and 1 ml (50 ml) for further rounds. Thus, the numbers
of DNA molecules in each library were ,6610
10 for the first round,
,6610
9 for the second round, ,3610
9 for the third round,
,2610
9 for the fourth round, and ,3610
8 for the fifth round. The
emulsions were incubated for 2 h at 37uC. To recover the water
phase, the emulsions (1 ml) were spun at 2,000 g and the
supernatant (750 ml) was mixed with 200 ml of quenching buffer
[Hanks’ balanced salt solution (HBSS) containing 0.5 M sucrose,
1% (w/v) BSA, 1% protease inhibitor cocktail (Nacalai Tesque),
100 mM GRGDS peptide (Peptide Institute, Inc.), 1 mg/ml salmon
sperm DNA (Stratagene), 1 mM biotin] and then centrifuged at
2,000 g for 5 min. The water phase was recovered and 1 ml of
water-saturated diisopropyl ether was added. The mixture was
inverted 20 times and centrifuged at 19,000 g for 5 min, and the
ether phase was removed. The water phase was exposed to a
vacuum to remove residual diisopropyl ether. The resulting DNA-
displayed peptide library was used for affinity selection.
Affinity selection on whole cells
Binding and selection experiments with DNA-displayed pep-
tides for receptors on whole cells were usually carried out in 1 ml
of HBSS containing 0.5 M sucrose, 1% BSA, 1% protease
inhibitor cocktail, 100 mM GRGDS peptide, and 1 mg/ml salmon
sperm DNA at room temperature with gentle shaking for 1 h. The
library was pre-incubated with Mock cells without recombinant
hAT1R receptor to remove nonspecific binders and then
incubated with the hAT1R-expressing cells. The cells were
washed several times with HBSS containing 0.5 M sucrose,
0.1% protease inhibitor cocktail, 10 mM GRGDS peptide and
10 mg/ml salmon sperm DNA. Finally 1 ml of HBSS with 0.5 M
sucrose was added and the selected DNA was eluted by exposure
to UV irradiation from a Black Ray XX-15 UV lamp (Ultraviolet
Products Inc.) at a distance of 15 cm (emission peak 365 nm,
300 nm cut-off, 1.1 mW intensity at 31 cm) for 15 min in a cold
room [22]. The eluted DNA was purified by ethanol precipitation
and amplified by PCR with KOD-plus DNA polymerase (Toyobo)
using PCB-labeled T7F forward primer and T7R-M (for library-I)
or T7R-M2 (for library-II) reverse primer (25–35 cycles of 94uC,
15 s; 62uC, 30 s; and 68uC, 60 s). The PCR products were
electrophoresed on 1% agarose gel, purified with a Recochip
(Takara Shuzo) and the QIAquick PCR purification kit, and used
as template DNA described in the previous section ‘‘Preparation of
DNA-displayed peptide libraries’’ for the next round of selection.
After several rounds of the library preparation and affinity
selection, to identify selected peptides, DNA was amplified with
non-labeled primers, cloned with a TOPO TA cloning kit
(Invitrogen), and sequenced with the ABI PRISM 3100 genetic
analyzer using Sta150F or Sta75F primer. Sequence logos
representation [45,46] of amino-acid sequences was created with
WebLogo Version 2.8.2 (http://weblogo.berkeley.edu/).
Streptavidin-fused peptide binding assays
Streptavidin-fused peptides for selected clones were prepared
separately by using the PURE system classic II kit with 20 nM
DNA for 1 h at 37uC. The streptavidin-fused peptides were
incubated with the hAT1R-expressing cells for 10 min at room
temperature in the presence 0–200 nM synthetic peptides (see
next section) as competitors, and washed as described in the
previous section. Then the binding proteins were recovered using
0.5 ml of lysis buffer (1% protease inhibitor cocktail and 4 M urea)
on ice for 30 min. The cell lysates were analyzed by 15% SDS-
PAGE and Western blot analysis using anti-T7?tag antibody
(Novagen) followed by HRP-conjugated secondary antibody
(Chemicon). The streptavidin-fused peptides with T7?tag were
quantitatively detected by an ECL chemiluminescence kit and
Hyperfilm ECL (GE Healthcare) [47].
Peptide Synthesis
Peptides of the LI5-series were synthesized by Peptide Institute
Inc. Peptides of the LII3-series were synthesized with an automated
solid-phase peptide synthesizer (model PSSM-8, Shimadzu). The
peptides were purified by reversed-phase high-performance liquid
chromatography (C18 column, 250 mm620 mm inside diameter)
with a linear gradient of water containing 0.1% trifluoroacetic acid
(TFA) and acetonitrile containing 0.1% TFA at a flow rate of
10 ml/min. The major fractions were lyophilized, and the peptides
were characterized by matrix-assisted laser desorption ionization
time-of-flight mass spectrometry (MALDI-TOF MS) (Autoflex,
Bruker Daltonics).
Supporting Information
Figure S1 Competition curves for selected peptides.
Streptavidin-fused Ang II was prepared with the PURE system,
incubated with the hAT1R/CHO-K1 cells in the presence of
various concentrations of synthetic peptides LI5-1 (filled circles),
LI5-2 (filled squares), LII3-2 (open circles), LII3-4 (open squares)
and LII3-5 (open triangles), washed and analyzed by 15% SDS-
PAGE and Western blot analysis. For details, see MATERIALS
AND METHODS.
(PDF)
Table S1 Oligonucleotide sequences. N=A, C, G or T;
D=A, G or T; M=A or C; R=A or G; K=G or T. T7F labeled
with photocleavable biotin (PCB) and T7R labeled with
fluorescein were used for preparation of labeled DNAs.
(DOC)
Acknowledgments
We thank Hideaki Takashima, Yumi Amano and Yuko Oishi in our
laboratory for helpful discussion and technical assistance. We also thank
Yutaka Shindo, Kotaro Oka (Keio University) and Hideyoshi Higashi
(Mitsubishi Kagaku Institute of Life Sciences) for technical advice and
support in the calcium imaging experiments; Teruhiko Matsubara and
Toshinori Sato (Keio University) for support with peptide synthesis; Tokiko
Hama (Mitsubishi Kagaku Institute of Life Sciences) for support in the
radio ligand binding assays; and Jun-ichiro Inoue (Institute of Medical
Science, University of Tokyo) for providing the human liver cDNA library.
DNA Display Selection of GPCR Ligand Peptides
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30084Author Contributions
Conceived and designed the experiments: ND TN NM HY. Performed the
experiments: NY HM YY TN. Analyzed the data: ND NY HM YY TN
KH. Contributed reagents/materials/analysis tools: ND NM KH HY.
Wrote the paper: ND KH HY.
References
1. Buck L, Axel R (1991) A novel multigene family may encode odorant receptors:
a molecular basis for odor recognition. Cell 65: 175–187.
2. Frederiksson R, Lagerstro ¨m MC, Lundin L, Schio ¨th HB (2003) The G-protein-
coupled receptors in the human genome form five main families. Phylogenetic
analysis, paralogon groups, and fingerprints. Mol Pharmacol 63: 1256–1272.
3. Lagerstro ¨m MC, Schio ¨th HB (2008) Structural diversity of G protein-coupled
receptors and significance for drug discovery. Nat Rev Drug Discov 7: 339–357.
4. Civelli O, Saito Y, Wang Z, Nothacker HP, Reinscheid RK (2006) Orphan
GPCRs and their ligands. Pharmacol Ther 110: 525–532.
5. Ozawa A, Lindberg I, Roth B, Kroeze WK (2010) Deorphanization of novel
peptides and their receptors. AAPS J 12: 378–384.
6. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are
there? Nat Rev Drug Discov 5: 993–996.
7. Howard AD, McAllister G, Feighner SD, Liu Q, Nargund RP, et al. (2001)
Orphan G-protein-coupled receptors and natural ligand discovery. Trends
Pharmacol Sci 22: 132–140.
8. Davenport AP (2003) Peptide and trace amine orphan receptors: prospects for
new theurapeutic targets. Curr Opin Pharmacol 3: 127–134.
9. Doorbar J, Winter G (1994) Isolation of a peptide antagonist to the thrombin
receptor using phage display. J Mol Biol 244: 361–369.
10. Szardenings M, Tornroth S, Mutulis F, Muceniece R, Keinanen K, et al. (1997)
Phage display selection on whole cells yields a peptide specific for melanocortin
receptor 1. J Biol Chem 272: 27943–27948.
11. Hennecke M, Otto A, Baensch M, Kola A, Bautsch W, et al. (1998) A detailed
analysis of the C5a anaphylatoxin effector domain: selection of C5a phage
libraries on differentiated U937 cells. Eur J Biochem 252: 36–44.
12. Houimel M, Loetscher P, Baggiolini M, Mazzucchelli L (2001) Functional
inhibition of CCR3-dependent responses by peptides derived from phage
libraries. Eur J Immunol 31: 3535–3545.
13. Bikkavilli RK, Tsang SY, Tang WM, Sun JX, Ngai SM, et al. (2006)
Identification and characterization of surrogate peptide ligand for orphan G
protein-coupled receptor mas using phage-displayed peptide library. Biochem
Pharmacol 71: 319–337.
14. Roberts RW (1999) Totally in vitro protein selection using mRNA-protein
fusions and ribosome display. Curr Opin Chem Biol 3: 268–273.
15. Doi N, Yanagawa H (2001) Genotype-phenotype linkage for directed evolution
and screening of combinatorial protein libraries. Comb Chem High Throughput
Screen 4: 497–509.
16. Dower WJ, Mattheakis LC (2002) In vitro selection as a powerful tool for the
applied evolution of proteins and peptides. Curr Opin Chem Biol 6: 390–398.
17. Lipovsek D, Plu ¨ckthun A (2004) In-vitro protein evolution by ribosome display
and mRNA display. J Immunol Methods 290: 51–67.
18. Ja WW, West AP, Delker SL, Bjorkman PJ, Benzer S, et al. (2007) Extension of
Drosophila melanogaster life span with a GPCR peptide inhibitor. Nat Chem
Biol 3: 415–419.
19. Doi N, Yanagawa H (1999) STABLE: protein-DNA fusion system for screening
of combinatorial protein libraries in vitro. FEBS Lett 457: 227–230.
20. Yonezawa M, Doi N, Kawahashi Y, Higashinakagawa T, Yanagawa H (2003)
DNA display for in vitro selection of diverse peptide libraries. Nucleic Acids Res
31: e118.
21. Sumida T, Doi N, Yanagawa H (2009) Bicistronic DNA display for in vitro
selection of Fab fragments. Nucleic Acids Res 37: e147.
22. Doi N, Takashima H, Wada A, Oishi Y, Nagano T, et al. (2007) Photocleavable
linkage between genotype and phenotype for rapid and efficient recovery of
nucleic acids encoding affinity-selected proteins. J Biotechnol 131: 231–239.
23. Tawfik DS, Griffiths AD (1998) Man-made cell-like compartments for molecular
evolution. Nat Biotechnol 16: 652–656.
24. Alon R, Bayer EA, Wilchek M (1990) Streptavidin contains an RYD sequence
which mimics the RGD receptor domain of fibronectin. Biochem Biophys Res
Commun 170: 1236–1241.
25. Parker SL, Kane JK, Parker MS, Berglund MM, Lundell IA, et al. (2001)
Cloned neuropeptide Y (NPY) Y1 and pancreatic polypeptide Y4 receptors
expressed in Chinese hamster ovary cells show considerable agonist-driven
internalization, in contrast to the NPY Y2 receptor. Eur J Biochem 268:
877–886.
26. Vanderheyden PM, Fierens FL, De Backer JP, Fraeyman N, Vauquelin G
(1999) Distinction between surmountable and insurmountable selective AT1
receptor antagonists by use of CHO-K1 cells expressing human angiotensin II
AT1 receptors. Br J Pharmacol 126: 1057–1065.
27. Olejnik J, Sonar S, Krzymanska-Olejnik E, Rothschild KJ (1995) Photocleavable
biotin derivatives: a versatile approach for the isolation of biomolecules. Proc
Natl Acad Sci USA 92: 7590–7594.
28. Arai R, Ueda H, Kitayama A, Kamiya N, Nagamune T (2001) Design of the
linkers which effectively separate domains of a bifunctional fusion protein.
Protein Eng 14: 529–532.
29. Hunyady L, Vauquelin G, Vanderheyden P (2003) Agonist induction and
conformational selection during activation of a G-protein-coupled receptor.
Trends Pharmacol Sci 24: 81–86.
30. Feng YH, Noda K, Saad Y, Liu XP, Husain A, et al. (1995) The docking of Arg
2
of angiotensin II with Asp
281 of AT1 receptor is essential for full agonism. J Biol
Chem 270: 12846–12850.
31. Miura S, Feng YH, Husain A, Karnik SS (1999) Role of aromaticity of agonist
switches of angiotensin II in the activation of the AT1 receptor. J Biol Chem 274:
7103–7110.
32. Miura S, Karnik SS (1999) Angiotensin II type 1 and type 2 receptors bind
angiotensin II through different types of epitope recognition. J Hypertens 17:
397–404.
33. Franc ¸a LP, Pacheco NA, Correa SA, Han SW, Nakaie CR, et al. (2003)
Angiotensin II-mediated cellular responses: a role for the 39-untranslated region
of the angiotensin AT1 receptor. Eur J Pharmacol 476: 25–30.
34. Khosla MC, Leese RA, Maloy WL, Ferreira AT, Smeby RR, et al. (1972)
Synthesis of some analogs of angiotensin II as specific antagonists of the parent
hormone. J Med Chem 15: 792–795.
35. Aumelas A, Sakarellos C, Lintner K, Fermandjian S, Khosla MC, et al. (1985)
Studies on angiotensin and analogs: Impact of substitution in position 8 on
conformation and activity. Proc Natl Acad Sci USA 82: 1881–1885.
36. Baker JG, Hill SJ (2007) Multiple GPCR conformations and signalling pathways:
implications for antagonist affinity estimates. Trends Pharmacol Sci 28:
374–381.
37. Rovira X, Pin JP, Giraldo J (2010) The asymmetric/symmetric activation of
GPCR dimers as a possible mechanistic rationale for multiple signalling
pathways. Trends Pharmacol Sci 31: 15–21.
38. Yonezawa M, Doi N, Higashinakagawa T, Yanagawa H (2004) DNA Display of
biologically active proteins for in vitro protein selection. J Biochem 135:
285–288.
39. Josephson K, Hartman MC, Szostak JW (2005) Ribosomal synthesis of
unnatural peptides. J Am Chem Soc 127: 11727–11735.
40. Murakami H, Ohta A, Ashigai H, Suga H (2006) A highly flexible tRNA
acylation method for non-natural polypeptide synthesis. Nat Methods 3:
357–359.
41. Takayanagi R, Ohnaka K, Sakai Y, Nakao R, Yanase T, et al. (1992) Molecular
cloning, sequence analysis and expression of a cDNA encoding human type-1
angiotensin II receptor. Biochem Biophys Res Commun 183: 910–916.
42. Chen N, Furuya S, Doi H, Hashimoto Y, Kudo Y, et al. (2003) Ganglioside/
calmodulin kinase II signal inducing cdc42-mediated neuronal actin reorgani-
zation. Neuroscience 120: 163–176.
43. Grynkiewicz G, Poenie M, Tsien RY (1985) A new generation of Ca
2+ indicators
with greatly improved fluorescence properties. J Biol Chem 260: 3440–3450.
44. Shimizu Y, Inoue A, Tomari Y, Suzuki T, Yokogawa T, et al. (2001) Cell-free
translation reconstituted with purified components. Nat Biotechnol 19: 751–755.
45. Schneider TD, Stephens RM (1990) Sequence logos: A new way to display
consensus sequences. Nucleic Acids Res 18: 6097–6100.
46. Crooks GE, Hon G, Chandonia JM, Brenner SE (2004) WebLogo: A sequence
logo generator. Genome Res 14: 1188–1190.
47. Dickinson J, Fowler SJ (2002) Quantification of proteins on Western blots using
ECL. In: Walker JM, ed. The protein protocols handbook 2nd edition. Totowa:
Humana Press. pp 429–437.
DNA Display Selection of GPCR Ligand Peptides
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e30084